NCT04002752 is a Phase 1 clinical trial of JNJ-73763989 in Healthy, sponsored by Janssen Sciences Ireland UC.

Who is sponsoring NCT04002752?

NCT04002752 is sponsored by Janssen Sciences Ireland UC.

What drugs are being tested in NCT04002752?

Interventions in NCT04002752: JNJ-73763989, Placebo.

Is NCT04002752 still recruiting?

NCT04002752 is currently completed. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT04002752

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

Completed Phase 1 Last updated 3 February 2025

What this trial tests

Phase 1 trial testing JNJ-73763989 in Healthy in 25 participants. Completed in 23 August 2019.

Timeline

4 July 2019

Primary endpoint
23 August 2019

23 August 2019

Quick facts

Lead sponsor	Janssen Sciences Ireland UC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	25
Start date	4 July 2019
Primary completion	23 August 2019
Estimated completion	23 August 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

JNJ-73763989 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen Sciences Ireland UC — full company profile →

Who can join

Adults 20 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of JNJ-73763989 in healthy Japanese adult participants following single-dose subcutaneous administration of 3 different doses of JNJ-73763989, Dose Level 1 (Panel A), Dose Level 2 (Panel B) or Dose Level 3 (Panel C).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.
Liu M, Wang Y, Zhang Y, Hu D, et al · · 2025 · cited 62× · PMID 40059188 · DOI 10.1038/s41392-024-02112-8
Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor.
Ramírez-Cortés F, Ménová P. · · 2025 · cited 22× · PMID 39628900 · DOI 10.1039/d4md00652f
Recent Update on siRNA Therapeutics.
Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, et al · · 2025 · cited 19× · PMID 40331977 · DOI 10.3390/ijms26083456
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Gane E, Yuen MF, Kakuda TN, Ogawa T, et al · · 2022 · cited 15× · PMID 35695169 · DOI 10.1177/13596535221093856

Verify or expand the search:

Other trials of JNJ-73763989

Trials testing the same drug.

NCT05275023 — An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death P · Phase 2 · completed
NCT05123599 — A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBe · Phase 1 · completed
NCT05005507 — A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis · Phase 2 · terminated
NCT04963738 — A Study of JNJ-73763989 in Adult Participants With Renal Impairment · Phase 1 · completed
NCT04585789 — A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus · Phase 2 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen Sciences Ireland UC trials

Trials by the same sponsor.

NCT04208399 — A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 · Phase 1 · completed
NCT04208386 — A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 · Phase 1 · completed
NCT04056611 — Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who A · Phase 2 · terminated
NCT04129554 — A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virolo · Phase 2 · completed
NCT03982186 — A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepati · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04002752 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Sciences Ireland UC
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04002752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing